Gene therapy, biotechnology research, and rare disease treatment by Taysha Gene Therapies

  • Viktoras Karapetjanc
  • 12.11.2026
Taysha Gene Therapies advances gene therapy for Rett syndrome: Will TSHA hold the MA-20?
Taysha Gene Therapies reported its third quarter 2026 earnings and provided an update on its clinical pipeline. The stock is little changed on the day, trading near $4.28.The company reported its ...
  • Igor Krasulya
  • 12.11.2026
TSHA-102 remains well tolerated with no severe adverse events in Rett syndrome trial, Taysha Gene Therapies reveals
Taysha Gene Therapies released its third quarter earnings, providing an updated snapshot of the company’s financial status and ongoing initiatives. The company reported that its lead gene ...
  • Igor Krasulya
  • 05.11.2026
Taysha Gene Therapies plans to release third quarter 2026 earnings and corporate update
Taysha Gene Therapies will announce its third quarter 2026 earnings and provide a corporate update next week. The company is inviting stakeholders to visit its website for more information about ...
  • Pavlo Kot
  • 20.10.2026
TSHA-102 clinical progress in Rett syndrome highlighted by Taysha Gene Therapies
Taysha Gene Therapies has provided an update on its TSHA-102 program, which is currently under clinical evaluation for Rett syndrome. The announcement was made following the company's ...
  • Hanna Syniavska
  • 15.10.2026
Taysha Gene Therapies to share TSHA-102 gene therapy advancements at CNSAM event
Taysha Gene Therapies announced plans to share updates on its TSHA-102 gene therapy program, which is currently in clinical evaluation, at the Child Neurology Society Annual Meeting (CNSAM). The ...
  • Eugene Komchuk
  • 01.10.2026
TSHA-102 clinical trial results featured by Taysha Gene Therapies at Child Neurology Society Annual Meeting
Taysha Gene Therapies announced it will present multiple encore presentations supporting its TSHA-102 clinical program for Rett syndrome at the 55th Annual Meeting of the Child Neurology Society. ...
  • Hlib Chabaniuk
  • 27.08.2026
Taysha Gene Therapies, Inc. launches webinar to advance patient-centered Rett syndrome trials
Taysha Gene Therapies, Inc. is promoting a webinar hosted by the Child Neurology Society featuring Dr. Arthur Partikian, a leading expert in Rett syndrome. The session is set to explore how ...
  • Andrey Mastykin
  • 11.08.2026
TSHA-102 program reaches milestone as Taysha Gene Therapies Inc. finalizes REVEAL and ASPIRE dosing
Taysha Gene Therapies Inc. delivered its second quarter 2026 earnings report and announced a major development in its TSHA-102 gene therapy program. The company confirmed that dosing has been ...
  • Andreas Kristo
  • 05.08.2026
Taysha Gene Therapies stock jumps 6.74% as TayshaGTx announces upcoming earnings update
Taysha Gene Therapies will announce its second quarter 2026 earnings and provide a corporate update next week. At the same time, Taysha Gene Therapies stock is up 6.7% on the day at $6.17.The ...
  • Yulia Slavina
  • 04.08.2026
Taysha Gene Therapies, Inc. prepares for Q2 2026 earnings release and company update
Taysha Gene Therapies, Inc. will disclose its financial results for the second quarter of 2026 and provide a corporate update next week. The company has invited stakeholders to access additional ...
  • Andreas Kristo
  • 03.08.2026
Taysha Gene Therapies stock trades down to $5.86 as company expands Catalent partnership
Taysha Gene Therapies announced it has expanded its partnership with Catalent through a commercial supply agreement for TSHA-102.TSHA-102 is an investigational gene therapy currently in clinical ...
  • Parshwa Turakhiya
  • 03.08.2026
Catalent to supply TSHA-102 under new commercial agreement with Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. has broadened its collaboration with Catalent by signing a commercial supply agreement for TSHA-102, the company’s investigational gene therapy currently in clinical ...
  • Dmytro Kharkov
  • 25.06.2026
Taysha Gene Therapies, Inc. to present TSHA-102 Rett syndrome clinical program at scientific meeting
Taysha Gene Therapies, Inc. plans to deliver presentations on its TSHA-102 gene therapy program at the 2026 International Rett Syndrome Foundation Scientific Meeting, scheduled for June 29 to July ...